Pfizer Inc. (PFE) Earnings Call Transcript & Summary
November 4, 2025
What were the key takeaways from Pfizer Inc.'s November 4, 2025 earnings call?
In the third quarter of 2025, Pfizer Inc. reported revenues of $16.7 billion, a 7% decline year-over-year, primarily driven by reduced demand for COVID-related products. Adjusted diluted EPS was $0.87, exceeding expectations, prompting management to raise its full-year EPS guidance to a range of $3.00 to $3.15. The company is optimistic about its non-COVID product performance and strategic initiatives, including the proposed acquisition of Metsera, which is expected to enhance its pipeline in the obesity therapeutic area.
What topics did Pfizer Inc. cover?
- Revenue Decline in COVID Products: Pfizer's revenues decreased by 7% year-over-year, largely due to a decline in COVID product sales, particularly Paxlovid, attributed to lower disease incidence and a lack of government stockpiling. Management noted, 'The decline was primarily due to Paxlovid, which experienced reduced demand from lower levels of disease incidents.'
- Strong Non-COVID Product Performance: Non-COVID products grew 4% operationally compared to the previous year, with strong contributions from key products like Eliquis and Vyndaqel. Management highlighted, 'Our non-COVID products performance was solid, growing 4% operationally versus the same period of LY.'
- Acquisition of Metsera: Pfizer is pursuing the acquisition of Metsera, which is expected to be dilutive to EPS in the near term but is viewed as a strategic move to enhance its obesity treatment pipeline. CEO Bourla stated, 'We believe the promise of the Pfizer and Metsera combination is strong and unwavering.'
- Guidance Update: Pfizer raised its adjusted diluted EPS guidance for 2025 to a range of $3.00 to $3.15, reflecting strong operational performance and cost management. CFO Denton noted, 'We are raising and narrowing our full year 2025 adjusted diluted earnings per share guidance by approximately $0.08 at the midpoint.'
- R&D Pipeline Progress: Management highlighted advancements in the R&D pipeline, including promising data from ongoing trials in oncology and immunology. Bourla mentioned, 'We are excited to present additional clinical data at the upcoming Society for Immunotherapy of Cancer Meeting.'
What were Pfizer Inc.'s November 4, 2025 results?
- Revenue: $16.7B (vs $18.0B LY, -7% YoY)
- Adjusted EPS: $0.87 (beat by $0.12)
- Non-COVID Revenue Growth: 4% (vs LY)
- COVID Product Revenue Decline: $4B (primarily from Paxlovid and Comirnaty)
- Adjusted Gross Margin: 76% (reflecting product mix and cost management)
- Full Year Revenue Guidance: $61B to $64B (maintained)
Pfizer's third quarter results reflect a mixed performance, with strong non-COVID product growth offsetting declines in COVID-related sales. The raised EPS guidance and strategic acquisitions signal confidence in future growth, but analysts remain cautious about competitive pressures and the potential dilution from acquisitions. Investors should monitor the progress of the Metsera acquisition and the performance of the R&D pipeline as key catalysts moving forward.
Earnings Call Speaker Segments
Hello everyone, and thanks for dialing in to Pfizer's earnings call. My name is Francesca DeMartino, and I serve as Chief Investor Relations Officer; the whole Pfizer team appreciates your participation; an audio webcast of this call can be accessed at pfizer.com. This morning, our third quarter 2025 results were issued through a press release, which you can find on our website at pfizer.com. With me today are Dr. Albert Bourla, our Chairman and CEO, along with David Denton, our CFO. Albert and Dave will each deliver some prepared remarks, after which we'll take your questions. Our leadership team members will be on hand for the Q&A portion. Before we begin, please be aware that forward-looking statements will be made and certain non-GAAP financial measures will be discussed. We ask that you review the disclaimers included in our slide presentation, the press release from this morning and the disclosures contained in our SEC filings, all of which can be found on the IR website at pfizer.com. Any forward-looking statements made on this call carry substantial risks and uncertainties, are valid only as of the call's original date, and no obligation is undertaken by us to update or revise any such statements. With that said, I'll hand things over to Albert.
Thanks, Francesca. Hello, everybody, and I appreciate you being on this call. These last several months have been a turning point for Pfizer; we feel genuinely enthusiastic about what lies ahead and are sure we're well positioned to keep generating value for patients as well as our shareholders. Results from our third quarter demonstrate the way we keep carrying out our work with rigor and concentration, even as we pursue significant strategic initiatives. I'll go over the main points, among them our deal with the U.S. government, which gave us much better visibility into how we're investing strategically in innovation and growth going forward. On top of that, with the Metsera acquisition we've proposed and the strides made since we wrapped up our licensing arrangement with 3SBio, along with important catalysts coming up, the power of our R&D pipeline keeps expanding. Our historic deal with the U.S. government marked a major step forward since it eliminated doubt across 2 essential policy areas. We managed to answer the administration's request to bring down prescription drug prices and match them to those of other developed nations, and in exchange for our pledge to put more money into U.S.-based manufacturing, we'll receive a 3-year grace period from certain U.S. tariffs. Now let me turn to the Metsera acquisition we've proposed. In our view, the offer from Novo Nordisk is illusory and cannot qualify as a superior proposal under the terms of the merger agreement we hold with Metsera, since it breaks antitrust law and carries a significant chance of never being completed. We take encouragement from the U.S. Federal Trade Commission's move to grant early termination of the HSR waiting period, something unprecedented amid a government shutdown, which opens the way to closing this transaction after the Metsera shareholder vote on November 13; given the pending legal action we've filed to enforce and preserve Pfizer's rights under the merger agreement, you can appreciate that we'll be constrained in what further details we can discuss on today's call. What I can tell you is that our confidence in the potential of combining Pfizer and Metsera is firm and unshakable; we're certain it will generate considerable value for shareholders and push innovation forward to deliver important medicines to patients within the high-growth obesity therapeutic area. Beyond that, we think Pfizer will hold unique advantages when it comes to developing and delivering new potential treatments, thanks to our demonstrated scientific and commercial strengths. Our R&D infrastructure spans the globe and comes with deep experience conducting clinical trials across large populations. Our commercial teams possess well-established abilities in delivering primary care therapies to patients; we've shown we can generate leading clinical, commercial and strategic momentum with key cardiovascular brands including Eliquis, Lipitor, Norvasc and the Vyndaqel family, and we intend to follow a similar playbook with Metsera as we restore Pfizer's cardiometabolic footprint. The licensing deal with 3SBio represents yet another instance of how we've strategically bolstered our pipeline. Promising Phase II efficacy and safety data for first-line metastatic colorectal cancer involving SSGJ-707, the PD-1 VEGF bispecific, was presented last month at the European Society for Medical Oncology meeting. Looking forward, there's real excitement on our side about sharing more clinical data at the Society for Immunotherapy of Cancer Meeting that's coming up. Our talks with regulators have also been encouraging — specifically around our strategy to realize the full potential of 707 through a comprehensive clinical development program. When it comes to delivering on 707, Pfizer holds some clear strengths. We bring extensive know-how in developing multi-specific antibody therapeutics, plus the capacity to apply distinctive combination regimens, which makes this promising cancer immunotherapy candidate a powerful addition to what we already offer in oncology. Beyond that, we've been making headway on other important programs within our late-stage R&D pipeline. That progress was on full display at ESMO last month, where we had more than 45 abstracts, 5 late-breaking presentations, and recognition in the Presidential Symposium. To begin with the Presidential Symposium: fresh Phase III results showed that Padcev combined with pembrolizumab cut the risk of recurrence and death by no less than half among patients with cisplatin ineligible muscle invasive cancer when administered both before and after surgery. This stands as the first and only regimen to boost survival when used ahead of and following standard of care for this group of patients. Armed with these unprecedented findings, we anticipate being able to considerably expand the U.S. addressable population — roughly 18,000 patients under the current label in metastatic urothelial cancer. And should additional positive data emerge and approval follow, that could mean up to approximately 22,500 more patients spanning both cisplatin-eligible and cisplatin-ineligible muscle invasive bladder cancer. We additionally shared follow-up results from the PHAROS single-arm Phase II clinical trial, which back Braftovi and Mektovi as a standard of care for patients with metastatic non-small cell lung cancer harboring a BRAF V600A mutation — V600E mutation; this updated analysis revealed a substantial median overall survival benefit of 70 to 47.6 months in treatment-naive patients with metastatic non-small cell lung cancer carrying a BRAF V600E 00E mutation; we're gratified by the ongoing robust year-over-year growth of Braftovi and Mektovi, marked by a 30 percentage point rise in new patient starts since the October '23 launch. In our view, the PHAROS trial findings could set a new benchmark with targeted combination therapies for its patient population; these results bolster the strength of our expanding lung cancer portfolio, which spans small molecules, ADCs, and our 707 bispecific; we remain confident in our ability to deliver treatments across the full lung cancer spectrum — a large and growing market projected to hit approximately $70 billion by year 2030. We also reported final overall survival results from the Phase III EMBARK trial assessing XTANDI in combination with leuprolide and as a monotherapy in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. As the first and only ARI-based regimen to show an overall survival benefit in this population, these findings underscore the potential benefit of XTANDI in this earlier line treatment setting; this reinforces our position for a product that is seeing strong demand growth in hormone-sensitive prostate cancer and rapid uptake in the approximate 16,000 U.S. The group of patients dealing with non-metastatic hormone-sensitive prostate cancer who have high-risk biochemical recurrence. I'd like to bring up one more piece of news regarding our sickle cell disease program. It makes us very happy that in the prior month, the FDA reached the conclusion that Pfizer can restart enrolling osivelotor studies in areas outside of Sub-Saharan Africa, as well as among people who have not moved away from Sub-Saharan Africa. We remain in discussions with regulatory agencies to figure out what the possible next steps are for Oxbryta. We look forward to providing additional information down the road about our major pipeline catalysts for 2026 over the coming years. Through disciplined execution and our ongoing emphasis on key products, in both the U.S. and important international markets, we keep strengthening our leadership position in our commercial portfolio. Our Vyndaqel family of products delivered 7% year-over-year global operational growth during the quarter. Robust demand confirmed that this serves as the foundation of treatment for patients with a heart condition of ATTR cardiomyopathy, assisting them in living longer and avoiding hospitalization. We feel encouraged by our ongoing strong market leadership. Internationally, we delivered 40% growth during the quarter in total patients on treatment. In the U.S., our ongoing double-digit demand growth mirrors strong diagnostic efforts, broad access and favorable affordability dynamics.
Nurtec keeps its top spot — it's number one in the oral CGRP category when it comes to primary care penetration across the U.S. Abroad, we saw growth thanks to sustained, robust adoption in important markets. On a global basis, operational growth for the quarter came in at 22% versus a year earlier. Our fresh consumer campaigns keep delivering solid results, which makes us happy, and the team has done a good job bringing new, persuasive clinical data to health care professionals. Padcev, yet another leader in its market within our portfolio, posted 13% global operational growth for the quarter compared with the prior year. Used alongside pembro, Padcev keeps broadening its use and now stands as an established standard of care in the first-line setting for patients battling locally advanced metastatic urothelial cancer. Vaccines remain a central priority for us in international markets. We're gratified by how strongly the Prevnar family has performed, fueled by <<inaudible>> and rollouts across a number of key markets. International additional growth of 17% year over year was recorded in the quarter. Pfizer holds the top position in pediatric pneumococcal vaccination, with public funding locked in through roughly 140 national immunization programs worldwide. Having rolled out in most major international markets, Prevnar Adult stands as the go-to leader among adult pneumococcal conjugate vaccines. Here in the U.S., where the quarter did bring a year-over-year decrease, we're happy with how Prevnar 20 performed overall. On the adult side, Prevnar kept its market-leading spot and expanded, helped by the broader recommendation covering adults over 50. Within pediatrics, which makes up roughly 60% of Prevnar revenues in the U.S., the timing of a government bulk order slipped, something that happens now and then; it's simply a matter of timing. Let me give you an update on the next-generation PCV programs. We'd previously guided toward a Phase III start for our adult 25-valent program in 2025, but now we intend to kick off that study next year, provided the FDA agrees with our approach. On the pediatric side, we anticipate fourth dose data from the Phase I/II study now underway in early 2025. Should the data be positive and regulators give feedback, we could potentially launch both Phase III programs in 2026, which would streamline how we develop things and fit our strategy of offering one vaccine across age groups. Keeping our leadership position in the PCV space is something we're dedicated to. Also, a reminder: our 25-valent vaccine candidate could deliver better immunogenicity against serotype 3, which remains among the biggest contributors to pneumococcal disease. Serotype 3 by itself is thought to account for about 20% of invasive disease among the 65-plus population in the U.S. and EU. Abrysvo likewise gained considerable international momentum, with 75% operational growth year over year in the quarter, driven by broader access in key markets. In the U.S., we're facing the headwind of a population that's harder to activate as we head into the third season of RSV. Even so, we keep reinforcing our position, holding a 59% market share in the U.S. for shipped-dose volume this quarter. Looking at the major strategic milestones we've hit over the past few months, along with the strong financial results we posted this quarter, you can see how we're creating long-term value while executing our 2025 strategic priorities in the near term. Through our dedication to simplifying where we focus and applying technology throughout the company, we're speeding up our progress and boosting productivity. This quarter brought yet another robust gross margin result. On top of that, we delivered adjusted diluted EPS that came in well above what was expected, despite reduced infection rates that drove a revenue decrease in our COVID-19 portfolio. Our business is doing well, and we're lifting the range for our full year 2025 adjusted diluted EPS guidance, while staying dedicated to our dividend as well. With that said, I'll hand things over to Dave.
Thanks, Albert, and good morning to everyone. First off today, I want to point out that the strong financial results we posted are a direct mirror of how consistently we've been carrying out our main strategic priorities; improving patient outcomes remains at the top of our list, along with hitting our financial targets. On top of that, the deal we recently struck with the U.S. government shows we know how to operate within a complicated external landscape. Thanks to our cost reduction efforts, we've achieved better operational efficiency and faster decision-making, and you can see that in the healthy operating margins posted this quarter. So far this year, margins have grown even with the drag from the acquired in-process R&D tied to the 3SBio transaction. Looking ahead, we anticipate stronger cash flow and more flexibility spread across our 3 capital allocation pillars. Creating long-term shareholder value is still our central aim; we'll keep putting money into the business for the long haul, as shown by our recent business development moves, while also returning capital to shareholders in a sensible way; with all that said, let me begin with our Q3 results, and after that I'll discuss our cost improvement efforts and our capital allocation priorities. I'll wrap up with some remarks about our 2025 guidance, which keeps getting better as the year goes on. During the third quarter of 2025, we brought in revenues of $16.7 billion, which is a 7% operational drop compared with the equivalent period a year ago. The main reason is a downturn in our COVID products. Most of that decline came from Paxlovid, which saw weaker demand stemming from fewer disease cases, plus the onetime Paxlovid government stockpiling from last year that was recorded in Q3 of 2024, and to a smaller degree, Comirnaty. That said, our non-COVID products turned in a solid performance, with 4% operational growth compared with the same period of LY. On the bottom line, reported diluted earnings per share for the third quarter of 2025 came to $0.62, while adjusted diluted earnings per share was $0.87, surpassing what we had expected thanks to our overall gross margin and cost management results. I should note that this profit figure carries a headwind of roughly $0.20 from acquired in-process R&D related to the 3SBio transaction. These results show how well our refined commercial strategy is working; we're still dedicated to focusing on key products and markets, optimizing how our commercial field resources are allocated globally, and zeroing in our market efforts on high priority areas. We enjoyed solid contributions throughout our product portfolios, led mainly by Eliquis, the Vyndaqel family and Nurtec, though those gains were more than erased by drops in Paxlovid and Comirnaty. Over the first 9 months of 2025, the products Pfizer has recently launched and acquired generated $7.3 billion in revenue, expanding about 9% operationally compared with last year. The slower growth seen in the third quarter relative to Q2 was mostly the result of the timing of pediatric CDC shipments for Prevnar and a onetime favorable effect in Q2 for Seagen products moving to a wholesale distribution model in the U.S. We intend to keep putting money behind these 2 product groups to fuel upcoming results and help make it possible for the company to substantially counter our LOEs across the coming several years. For the third quarter, adjusted gross margin came in at roughly 76%, mostly a reflection of the quarter's product mix along with sustained robust cost control across our manufacturing footprint. As a reminder, during the last 2 years, our adjusted gross margins have mostly stayed within the mid- to upper 70s, if you set aside Comirnaty, which carries a 50 to 50 profit split with BioNTech, our partner. By the close of '27, we anticipate $1.5 billion in savings from Phase 1 of the manufacturing optimization program, which will support our goal of long-term operating margin expansion. Looking ahead, managing costs throughout our manufacturing network stays a leading priority. For the third quarter of '25, total adjusted operating expense reached $7 billion, up 21% operationally compared with LY, largely propelled by the acquired in-process R&D expense tied to 3SBio. If you take out the 3SBio deal, adjusted operating expenses shrank by roughly $150 million compared with last year. Turning to the components, adjusted SI&A expenses fell 3% operationally, mainly because of targeted investments and continuous productivity gains that produced lower marketing and promotional spending across various products. Adjusted R&D expense likewise declined 3% operationally, the result of a net reduction in spending from pipeline focus and optimization, including growth in our digital capabilities. And lastly, acquired in-process R&D expenses rose $1.4 billion, mostly attributable to the 3SBio deal. As our adjusted S&A and R&D expenses show, we stay disciplined when it comes to managing operational expenses. Q3 reported diluted earnings per share came to $0.62, while adjusted diluted earnings per share was $0.87, helped by our efficient operating structure. In addition, EPS got a boost from our effective tax rate, chiefly due to favorable shifts in the jurisdictional mix of earnings plus tax benefits tied to global income tax resolutions across multiple jurisdictions covering multiple years, partly offset by the previously mentioned 3SBio acquired in-process R&D charge. We remain disciplined on expense management, advancing several cost improvement programs while keeping our focus on generating operating margin expansion in the years ahead. Phase 1 of the manufacturing optimization program delivered savings during the third quarter. Beyond that, we are still on track to meet our target of at least $4.5 billion in cumulative net cost savings from our ongoing cost realignment program by the close of this year. As a reminder, altogether for these programs, we anticipate roughly $7.7 billion in savings by the end of '27 to generate operational efficiencies, reinforcing our business with the potential to add significantly to our bottom line across this period. Out of those savings, about $500 million identified in R&D will be put back into the pipeline, which we expect by the close of 2026. With that, let me now briefly address our capital allocation, which is set up to boost long-term shareholder value. Our approach involves sustaining and increasing our dividend as time goes on, putting money back into the business at suitable levels of financial return, and conducting share buybacks that add value; during this year's first 9 months, we gave back $7.3 billion to shareholders through our quarterly dividend, spent $7.2 billion on internal R&D, and put roughly $1.6 billion into business development transactions, mainly reflecting the 3SBio licensing deal. Just to remind everyone, following the 3SBio deal, we have about $13 billion in business development capacity. During Q3, we revealed plans to acquire Metsera for around $4.9 billion, plus additional contingent value rights linked to successful pipeline progression. We anticipate funding this transaction with a combination of cash on hand and debt. Through 2030, we expect the deal to be dilutive as we keep investing to support additional promising late-stage pipeline assets. To be specific, we presently anticipate the Metsera transaction will be about $0.16 dilutive to 2026 adjusted EPS. We also anticipate an extra $0.05 of dilution in '26 stemming from the 3SBio deal, which closed during the third quarter. Having said that, we think these 2 deals establish a strong potential revenue growth trajectory in 2030 and beyond.
And finally, during the initial 9 months of '25, cash from operations came to roughly $6.4 billion, and that figure reflects the $1.35 billion upfront payment tied to the 3SBio transaction. At the close of the third quarter, our gross leverage stood at about 2.7x. That being said, once the Metsera transaction closes, we anticipate leverage will exceed the 2.7x target. Over time, we expect to reduce leverage back to target levels so we can keep supporting a balanced capital allocation between reinvestments and direct returns to shareholders. Let me now move to our full year 2025 guidance. As Albert mentioned in September, we secured a new voluntary agreement with the U.S. government, one that will help make sure U.S. People who need medicine will spend less at the pharmacy counter, and in return we gain the certainty we need to stay focused on running the company and funding the innovations we'll bring to market down the road. Our 2025 guidance remains untouched by this deal, but when we look at 2026, we anticipate it will weigh on our financial outlook. For the full year 2025, we continue to expect revenues somewhere between $61 billion and $64 billion. Operationally, our non-COVID products continue to deliver strong results and are running ahead of what we planned; even so, we're seeing weakness in our COVID products, driven by fewer vaccinations and lower rates of COVID infection; in addition, our guidance builds in a beneficial revenue effect from foreign exchange rates. Beyond that, our projection for adjusted R&D is now somewhere between $10 billion and $11 billion, and we're looking at an effective tax rate of about 11%. Adjusted S&A, meanwhile, stays where it was. Thanks to how well we've done up to this point, plus what we see for the fourth quarter — and a cost structure that's more efficient — we're lifting and tightening our guidance for full year 2025 adjusted diluted earnings per share, moving the midpoint up by roughly $0.08, which puts us at $3 a share to $3.15 a share. One thing I'd like to stress: our adjusted diluted earnings per share guidance goes a long way toward removing the risk tied to COVID trends that are currently running below what we'd anticipated. Wrapping up, our dedication to increasing the worth of what we offer in our portfolio and pushing innovation forward to make our pipeline even stronger hasn't changed; now that our balance sheet is in better shape, we intend to continue putting capital to work in effective ways. What we're striving for is greater R&D output by leveraging digital resources, AI among them, putting money first into the R&D programs that matter most, and creating fresh growth via business development. On top of all that, we keep surpassing what was expected of us and turning in solid results, and this holds true even with COVID cases staying at a low level. Such steady achievement makes clear how resilient we are and how devoted to doing things excellently. Regardless of how difficult conditions outside our company may become, we keep working to improve cost efficiency and bring about better operating margins by boosting productivity and streamlining our processes. To wrap up, thanks to the deal we just reached with the U.S. government, our attention can turn to carrying out our strategy and strategic priorities throughout the business, so we can bring new medicines to patients and build greater long-term value for shareholders. One last point: we expect to give guidance for 2026, in all likelihood before this year is over. With that, I'll turn it back to Albert, and then we'll begin the Q&A.
Thank you, Dave. So operator, please assemble the queue.
When it comes to Metsera, I'll leave those to my fellow analysts, though I am interested in your thoughts. I have a few additional things to ask about on the commercial front. First, Vyndamax — clearly there's more competition in that area now. The results caught me off guard, since there was a slight drop from one quarter to the next. Could you talk about what's happening with pricing and the share dynamics in that market, given the new entrants? Then I have a similar thing to ask regarding Padcev. The data you presented at ESMO was excellent, no question. But at least for this quarter, commercial uptake came in a bit below our expectations. So assuming you secure the muscle invasive indication here shortly, how do you see that affecting uptake for the program and creating upside relative to the current figures?
Thanks, Vamil. Aamir?
Absolutely. Vamil, I appreciate that question. Let me begin with what you asked about Vynda. I'd like to establish a few baseline points regarding Vynda first, and after that I'll get into how it performed during the quarter. Clearly, there are new competitors in this space, and it's worth pointing out that Vynda remains the sole ATTR-CM therapy demonstrating statistically significant decreases in mortality as well as CV-related hospitalizations, both combined and on its own. It's also the sole option offering a once-daily capsule, safety comparable to placebo, and almost full TTR stabilization. Across the U.S., we've secured 90% access for Vyndamax. Now, turning to the quarter, a few distinct dynamics are at play. To begin with, demand growth came in very strong, and our ongoing leadership in market share backs that up — obviously on a TRx basis, but also when it comes to first-line share. That said, 2 gross-to-net pressures counteracted the volume gains. The first is the IRA manufacturer rebates, something we've discussed previously; the second is the payer contracting that occurred during the third quarter, which we hinted at last quarter. So Vyndamax is delivering precisely as we anticipated and in line with our guidance, and results keep reflecting robust diagnosis, wide access, and better affordability trends, all of which will keep driving our volume higher. We do observe a competitor that <<inaudible>> is capturing some first-line share among treatment-naive patients, while <<inaudible>> has produced only minimal switching so far. As we think ahead about Vynda, several of these patterns will persist into Q4 as well, where we anticipate volume will keep growing, though the 2 GTN factors I mentioned will definitely affect our net sales. Even so, Vynda is delivering the way we expected. Regarding your Padcev question, once again we're quite encouraged by Padcev's trajectory. We examine it through 2 different lenses. The first is the a/mUC population, where our share currently sits at roughly 55% for cisplatin-ineligible patients and between 45% and 50% for cisplatin-eligible patients. That leaves room for us to keep concentrating on that portion of the market. I believe your question about how Padcev did relative to consensus ties back to what Dave said — namely that when we integrated the Seagen products into the Pfizer portfolio during Q2, we shifted from a drop ship approach to a wholesaler approach. That created a onetime increase in our Q2 sales. So you need to grow the products off that figure, adjusted for 2 to 3 weeks of inventory. As we cycle into Q4, we anticipate the entire Seagen portfolio, Padcev included, will get back to growing. And last, regarding MIBC, we're enthusiastic about what could come from the ongoing 303 trial as well as the 304 trial, since that would unlock a group of roughly 22,000 patients, supporting the next increase in Padcev's growth.
Nice work on this quarter's results. My question concerns Metsera. Can you walk us through what lies ahead legally? Pfizer's position, as I understand it, is that Novo buying Metsera would harm competition. And should the FTC block it, anticompetitive effects could still arise. So please take us through the timeline and how the courts will weigh Pfizer's arguments.
Thanks, Dave. Like I mentioned during my opening remarks, offering comments is quite hard while so many legal matters remain unresolved, correct, at this very moment. Still, I'll restate what I already said, and that partly addresses your question, though not regarding timing: we fail to see any way Novo's transaction could be better; it amounts to an unlawful effort by a company from abroad to sidestep antitrust rules, exploiting the government shutdown. Their aim isn't obtaining these products, it's eliminating them. They seek to catch and kill a rising rival, a major antitrust problem considering Novo's commanding market position; therefore, the only thing I can add is that every legal avenue remains open to us. Thank you. Let's take the next question.
I suppose this is mainly for Albert and Dave — a quick, big-picture BD question. Should Metsera not pan out for whatever reason, what would the approach be? Then, regarding 2026, is there any preliminary sense of the guidance tailwinds and headwinds, particularly how OpEx should be modeled with Metsera versus without it? Also, could you give us more detail on how we ought to view the dilution you referenced related to the recent MFN deal with the administration?
Since there are many financial components as well, I'll direct that question to Dave. After that, should Andrew wish to contribute anything regarding BD, he can.
Yeah. So perhaps we can begin with business development. Clearly, the company still has considerable resources available to figure out and successfully execute deals that bring science in-house, and we'll keep pushing hard on that front across all 4 of our therapeutic areas, and we'll keep searching worldwide for possible acquisition targets that can help deliver new and innovative medicines to patients. So that remains a very active, ongoing priority for the company. I think it's probably a bit soon to speak precisely about 2026. You heard me offer a little color in the sense that obviously, we are making investments today, and those investments extend into '26 and beyond with either Metsera or 3SBio to bring these innovative medicines to market. Those will have a somewhat dilutive impact on our operating performance next year. We will then pull all of that together along with the puts and takes of '26 when we provide guidance by the end of this year.
Andrew, is there anything you want to add regarding BD?
Yeah. I'd second Dave's point that we're quite active across every geography, with China standing out in particular. You saw the 3SBio deal, which gives us a foundational asset capable of serving as the backbone across several indications. That holds true both in China and elsewhere, spanning all the major therapeutic areas. We've grown our team in China specifically, and our efforts there are very active. Once there's something for us to share, you'll definitely hear about it first.
I suppose this one is for Albert or Dave. Considering the manufacturing spending you're undertaking under the MFN agreement alongside the operational cost efficiencies, how would you rank those two as priorities? I think both appear to have time frames of 3 years. I'm simply attempting to understand the incremental dollar and the strategy behind it.
Dave?
Absolutely. There are definitely key pieces to what we're doing. From a production standpoint, we're going to put money into the U.S. — that part is clear. Right now we're figuring out, alongside the new deal we've reached with the U.S. government, the best way to put our capacity to work over here and expand it further. So expect more details; we'll also shed some light on this when we roll out guidance for 2026. That said, we'll manage to upgrade our operating — our manufacturing operating infrastructure while also putting capital into manufacturing within the U.S. And those 2 things don't have to be entirely at odds. We can pull off both.
Let's take the next question.
We appreciate you taking the time to respond to us today. What I was hoping to get clarity on — and this may be yet another net zero question, though approached differently — is this: what do you believe enabled Pfizer to secure that remarkable early end to the waiting period granted by the U.S. Federal Trade Commission? That would be extremely useful to know.
I'm not certain I grasped what you're asking.
The FTC clearance.
Why the FTC clearance?
If there are any factors that drove the early...
Should there be any — actually, my view is that the FTC arrived at that conclusion independently. Naturally, this matter was on their radar. Therefore, I won't presume to represent their position, yet their judgment was that it makes sense, while a foreign bid is in the process of superseding, to simply let our transaction go public, and that has now become evident; so that's the whole of it.
To me, this shows even more how solid our deal is, along with the route toward clearance and the route that lets us keep building out these products and bring them to market very quickly. That benefits patients over the long term, and it benefits prices over the long term under our management and our guidance with these assets.
Absolutely, and no one should be caught off guard by that, correct, since all of us recognize that this represents the very definition of an antitrust clash. When it comes to the whole Metsera pipeline, that's the complete Novo pipeline, and on top of that they hold a dominant position with the products they currently have. Naturally, the FTC would have concerns about something like that. I'm not going to claim to speak on their behalf, but it's a situation that — everyone gets it. All right. Let's take the next question, please.
I might have a couple. In the past, you described Elrexfio as a major long-term growth engine. We saw that the MagnetisMM-5 study’s data has been moved to 2026; we’re aware that J&J ran a comparable study in a comparable patient group that recently reported; could you remind us of any possible distinctions between your study and theirs, and why the timing could differ even though both began at roughly the same point? My second question is a clarification regarding Paxlovid trends this quarter; based on our calculations, it appears the price for each prescription rose compared with the prior quarter. So I’m wondering whether there are any one-time items we should factor in when considering fourth-quarter trends.
Okay. Chris?
Yeah, I appreciate the question. So regarding MagnetisMM-5, as you're aware, it involves dual class exposure. It could come later in this year or at the start of next year — the trial is event-driven. That means the timeline might move if events don't occur, and we're not able to speculate on that. But as you might expect, when events aren't occurring in the study, that's frequently a good sign. So we'll keep tracking the events and ideally share results in early next year.
Right. As for Paxlovid, I don’t see any meaningful shift in pricing. There may be some variation in the mix of channels and that kind of thing, but from that angle, nothing major.
Thank you for clarifying, Dave. Let's go to the next question please.
One thing I wanted to ask about is the Phase III EZH2 data readout coming up in CRPC. It caught my attention that this trial gets highlighted so strongly, since it could potentially broaden the XTANDI franchise. After looking at a few of your food effect studies, what makes you confident that target exposure will be sufficient? And separately, how are you thinking about overall survival? Is a 20% to 30% benefit something we might see?
Chris, over to you.
I appreciate that question. So this is yet another internally found, first-in-class asset — our EZH2 program. In the past we reported randomized results demonstrating a meaningful PFS advantage among all patients with late-line metastatic castration-resistant prostate cancer. At this point, three Phase III trials are underway. As you mentioned, the initial readout will cover metastatic hormone-resistant prostate cancer following abiraterone, and we anticipate that within the next few months. We also recently shared data at ASCO — randomized findings addressing your food effect question — involving 875 milligrams given twice daily alongside food, and those results proved comparable to the dose we currently employ in Phase III, with lower GI adverse events; therefore we have confidence in the dose chosen.
Regarding this year's guidance, you've obviously repeated the $61 to $64 total revenue range, but at the time you initially provided that guidance, you mentioned roughly $9 billion in total COVID-19 sales for the year, and given that you've recorded only a bit more than $4 billion so far this year, I'm just curious about your thoughts on whether that $9 billion remains attainable for the entire year. And if it isn't, which other assets would you identify as probably making up that shortfall and providing you with confidence to repeat the total sales guidance?
Thank you. Dave, please?
Yes. On that point — you've got it exactly right, Kerry, and like you mentioned, I'd say hitting the bottom end of our revenue guidance would require the COVID franchise to keep seeing only a very slight pickup for the rest of this year, especially in the U.S. But the COVID franchise, as you're aware, goes through ups and downs. Should a COVID wave hit within the next few months, you could watch utilization jump sharply. That's the reason the range is so wide. Let me also note that with the earnings per share guidance range we gave, we've taken the risk out of the COVID franchise, because if these trends hold, we'll land nearer the bottom end of that range, and we'll still be able to meet our earnings commitment.
Thank you, very clear, Dave. Let's move to the next question please.
I'd like to get a sense of how you approached setting the price for the GLP-1 and medicines in this category, because — I mean, there's a news piece even today indicating a figure of roughly $150. So it looks as though pricing is moving in just a single direction. If that's the situation, I mean, how do you defend the amount you're handing to Metsera and, more broadly, the obesity space as time goes on — how do you view that alongside this downward pricing trend for the category?
Yes. Thanks. This is competition as well, and competition drives prices lower. And naturally, they aim not to limit competition. But in any event, the — yes, we — when we ran our numbers, we factored in that GLP-1 prices likely will begin to fall. So I don't know what's going to be announced at this point. But when we ran our numbers, we had already factored that in. Thanks, Mohit. Let's move on to the next question.
Could you say more about what's behind the postponement of the start of the Phase 3 study for the 25-valent pneumococcal vaccine in adults? You'd noted the condition that this depends on whether the FDA agrees with your strategy. So has the tone of those conversations with the agency shifted? Might it be that surrogate endpoints can no longer get approval?
Many thanks. Chris?
Absolutely. Thanks for asking that. For every one of our vaccine initiatives, we are, as you'd expect, collaborating quite closely with the FDA and other regulatory bodies regarding how the trials are designed and what the endpoints should be. With respect to PCV25, assuming the data come back positive and the FDA gives its feedback, our plan — as we've said — is to launch that trial along with the pediatric 25-valent program in the coming year. What that means is the pediatric and adult trials will be brought into alignment. Data from the fourth dose in the pediatric trial should reach us in the early part of next year. That gives us what we need to synchronize the 2 trials. It simply makes things smoother. This 25 vaccine candidate targets 25 serotypes — in particular, I should highlight serotype 3, which we addressed previously, since this vaccine was built to deliver notably stronger immunogenicity against serotype 3, a serotype that right now accounts for as much as 20% of infections across the U.S. and the EU; and in order to maintain our leadership position, we're also pressing ahead with research on our fifth generation, covering 30-plus serotypes, and we'll bring you a further update on that in 2026.
Thank you, Chris. Operator the next question please.
Let me ask maybe a couple of things about MFN. The first is somewhat broader. When you consider MFN applying to new launches down the road, how do you view what that implies for revenue outside the U.S.? I suppose one way to interpret it is as a net positive, since you'd be able to charge more. Another way is as a net negative, because at those steeper prices the reimbursement barrier becomes harder to clear; it might also be neutral. How did you picture things unfolding internationally when you agreed to that deal? Then the second thing is just wanting a bit more detail regarding the MFN effect in 2026. I believe you referenced some dilution there, but could you give any further quantitative measures of just how big a headwind that represents for the coming year?
Yes. I apologize if I turn to Dave to answer you, which he will do; guidance will be given by us at the close of the year, and everything will be folded into it, that item included along with the other matters he was discussing. So regardless of how much you talk with us, I doubt you'll extract additional words from us. Regarding new launches internationally, naturally we are waiting to observe how matters might unfold. That price gap cannot be maintained. We are referring to the smaller set of nations abroad that this affects. And with those nations, our hope is that they'll recognize they must alter how they set prices for their products going forward. Naturally, a bit of assistance from the U.S. government and USTR via trade talks could also bring that about; and my read is that <<inaudible>> and the U.S. trade representatives are extremely, extremely dedicated to eliminating this. So we shall see how it unfolds; but in theory, if the prices over there are — they are — we don't settle on a reasonable approach to pricing our products, plainly, reimbursement won't be obtained there, and we will set their prices at a level that won't impact the U.S. price. Thank you. And now let's move to the following question, please.
To start with Metsera — I understand this may now sit with the M&A attorneys and the antitrust counsel. Still, from an R&D standpoint, can you assure us that every piece of upcoming data will get reviewed, such as the monthly switch and whether GI tolerability holds up, and even more crucially, the early amylin plus GLP combination results? Then, on a separate note, a Phase IIb study you launched in atopic derm with an oral agent caught my attention. Might you verify whether it is a STAT6 inhibitor? Also, did Phase I let you assess how strongly STAT6 was inhibited?
Well, regarding Metsera, it's straightforward — should they hand us data or make it public, naturally we will; we are keen to review it, and our expectation is that it will be favorable. As for the second item, I'll turn it over to Chris for his thoughts.
Thanks, Umer, for posing a question about what we have in our I&I portfolio. Let me just confirm — is PF9820 the one you mean?
I don't think he can come back in.
Yes, that's right. It's a STAT inhibitor. I'd like to emphasize that our current I&I portfolio is highly differentiated, with no fewer than 5 molecules that were discovered and developed internally, and most of them moved forward at a notably faster pace. That includes, of course, p40/TL1a, which we developed alongside Roche, or rather is being developed alongside Roche, and which targets IL-12 and IL-23 through p40. Then there are our 2 tri-specifics aimed at IL-4, IL-13, TSLP, or IL-33; both are now moving into Phase II for atopic dermatitis as well as other Th2-related conditions. There's also Litfulo, with a Phase III study underway in nonsegmental vitiligo — a JAK3/TEC inhibitor that is likewise differentiated and discovered in-house. And then there's the early STAT6 program, just entering Phase II, which has the potential to be a first-in-class oral option. Right now we're continuing to refine the dose and the formulation, and we expect to give you an update on that program in 2026.
Thank you very much, next question please.
I have two things I'd like to ask. First, regarding the arrangement on drug pricing with Trump, what is it that Pfizer is permitted to do which rival firms won't be able to do, apart from AstraZeneca, naturally? Then, about Metsera — the data appears to be more alike than distinct from what competitors have shown, and Metsera's disclosures were not fully transparent, which raises significant concerns. A number of other large-cap pharma companies skipped over Metsera while chasing other products, which confirms the me-too criticism. None of this warrants a bidding war, or even a drawn-out legal fight. Is Pfizer's resolve to keep going supported by meaningful confidential information, or is it just a wish to be a participant in obesity? Or might Pfizer actually accept the arguments I just made and simply decide to walk away?
Thank you. On your first point about drug prices and whatever we possess that other firms might lack — I'm unable to respond, since I have no knowledge of what those other firms hold. As you're aware, these talks happen between the administration and each company separately, which likewise guarantees there are no antitrust problems. And naturally, they're confidential too, since that's what the administration and the agreements set out — that we ought to preserve confidentiality around those assets. So I'm aware of what we're receiving. A portion of it became public, and a portion sits within the broader, very lengthy deal, but I have no idea what others will take. On Metsera — look, we've examined the data. We conducted thorough due diligence, and we set a price — we valued the asset at a level we believed delivers enormous value to Metsera's shareholders and to Pfizer's shareholders, since those assets we favor, once in our hands, will of course deliver a notable competitive advantage. What you're witnessing now is a renewed attempt to cut down and kill this rising competitor, Pfizer, and to accomplish that by sidestepping antitrust review and effectively obtaining control — de facto control — of the company, as they'd turn into the biggest shareholder and the biggest creditor with no regulatory examination whatsoever. That's everything I can say. And I'm — we'll see how it unfolds.
If the Metsera deal goes through, Dave, what short-term things do you need to weigh in order to keep raising the dividend and then bring down leverage — and you mentioned that — when might you also be in a position to begin buying back stock? Or, given all this BD, does that rank lower on the list?
Evan, that's a really good question. Of course, what you've witnessed from us across the past 1.5 years, or 2 years, is a real push into productivity throughout our platform. Thanks to that productivity, we've brought leverage down from about 4x to 2.7x. What that has done is give us more flexibility to pursue business development while also sustaining and increasing our dividend as time goes on. That improvement cycle on the productivity side is now something baked into the company. We'll keep at it. Across the whole enterprise, we'll keep at it. From an R&D standpoint, we'll keep prioritizing ourselves. It's clear that by the end of the decade, we hold a number of assets we view as central to this company's growth. From a pipeline standpoint, we intend to put money behind those assets, and we intend to put money behind the product categories we've either bought and/or rolled out recently, since those are ultimately what will let us offset the LOEs across the coming several years. So all of that is within reach for us. Buybacks are a significant lever in our toolkit. Over the short term, that's not a tool we'll be employing. The balance sheet has to get back to where it needs to be. And we — once more, at this point, business priorities sit ahead of that. Great question. Thank you.
Okay. So now I think let's get the last question.
I have two questions, if that's alright. I understand there's a limit to what you can share regarding Metsera right now. From a modeling standpoint, though, if we're considering extra balance sheet capacity for dealmaking, what amount would you figure — presuming that in 2026, under your own internal budgeting, you're setting aside some capacity and not directing it toward Metsera at present, that would be quite useful; and regarding 3SBio, I realize the deal has only just closed and certain trials have only just begun. At what point should we anticipate data news flow emerging from that deal? Is it more likely a 2027 event? Or will there be any interim readouts or updates during '26?
Thank you. I believe Dave can address the Metsera modeling?
Yeah. So when you're looking at BD capacity, like I mentioned in what I'd prepared to say, we're coming into the third quarter with roughly $13 billion of capacity available, so given that...
Chris, let’s make sure we’re clear on the <<inaudible>>.
Sure — regarding how the data are coming out, I’ll recap: at ASCO 2025, we presented Phase II monotherapy results in first-line non-small cell lung cancer, and those showed an objective response rate of 65%. At ESMO, Phase II combination data with chemotherapy <<inaudible>> mFOLFOX6 were reported for first-line metastatic castration — apologies, metastatic colorectal cancer — and the response rate there was close to 60%. At SITC, we’ll share more data, including combination data in lung cancer, and as you’ve just seen, we’ve announced two Phase III programs beginning this year: one in first-line non-small cell lung cancer and one in first-line colorectal cancer. In the next few weeks, we’ll also give you the complete development plan at an event, and that will demonstrate the broad — the breadth and depth — of our clinical development program for 707.
Appreciate that, Chris. And many thanks to everyone for tuning in. A number of important strategic objectives have been reached by us. Our results for the quarter came in strong, our confidence in this business is high, and that is the reason we are lifting our adjusted diluted EPS guidance; and naturally, we are keeping our revenue outlook even with the weakest COVID trends at present. So thanks for your interest in Pfizer, and I wish all of you a great week.
That brings today's session to an end. We appreciate everyone taking part. Feel free to drop off whenever you like.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Pfizer Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Pfizer Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.